Stereotactic MR-Adaptive Radiation Therapy for Early-stage Renal Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The purpose of this study is to investigate the use of an MR-guided linear accelerator to treat early stage renal cancer patients, considered inoperable or in patients declining surgerys. The study will collect efficacy, toxicity, and dosimetry data and assess the degree of improvement provided by this treatment technique. The primary objective is to evaluate whether magnetic resonance imaging (MRI)-guided radiation therapy (MRgRT) for primary renal cancer has an improved toxicity profile relative to conventional computed tomography (CT) based radiation therapy, as measured by the frequency of grade 2+ adverse events following MRgRT as per Common Terminology Criteria for Adverse Events (CTCAE) version 6.0.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek co najmniej 18 lat
- •Potwierdzony rozpoznaniem raka nerki (RCC) lub diagnoza obrazowa, gdy biopsja nie jest wskazana
- •Pacjent nie może przejść operacji lub zabiegu ablacji, lub świadomie ich odmawia
- •Guz o wymiarze poniżej 7 cm, bez przerzutów do węzłów chłonnych ani odległych
- •Dobry ogólny stan zdrowia (ECOG 0-2)
- •Oczekiwana długość życia co najmniej 2 lata
- •Pacjent jest odpowiednim kandydatem do radioterapii sterowanej MRI
✗ Disqualifies
- •Przeciwwskazania do badania MRI (np. stymulator serca, zastawki metalowe, silna klaustrofobia)
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- August 21, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
NYU Langone Health
New York, United States
Trial contact
Nicholas Colangelo, MD, PhD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/22/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.